Brought to you by 
Sirion gets topical eye candidate from Senju
10 Jul 2006
Executive Summary
In its second deal this month, Japanese pharma company Senju Pharmaceutical is continuing to out-license ophthalmic compounds, this time giving newly founded Sirion Therapeutics (eye diseases) exclusive US rights to the Phase III corticosteroid difluprednate for the treatment of ocular inflammation such as severe uveitis.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sirion gets topical eye candidate from Senju
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice